Oncology and Technology with Carevive

Integrating patient-reported outcomes (PROs) into clinical practice is an increasingly promising strategy for improving patient engagement, symptom control, and clinical outcomes, including reducing avoidable hospitalizations and emergency room visits. Furthermore, recent data also shows that PRO-based proactive symptom monitoring may increase cancer patient survival. Now is the time to engage in discussions on practical applications of ePRO and finding the right balance of people, process, and technology. Recent advances in technology and survey methods may provide a solution to capturing PROs. There is evidence that the PRO approach can improve patient-clinician communication, ultimately improving a patient’s overall quality of life. An ePRO system can play a key role in clinical decision-making, as symptom management would improve and clinicians would be more aware of how a patient feels. PROs are finding a significant place in healthcare quality metrics, and PROs are sometimes thought to be more reliable than clinician-reported data. The challenge continues to be adopting service workflows to collect this information from patients, and electronic PROs (ePROs) have definitely enhanced this process. In this webinar recording, you will hear from a panel of experts discuss: Latest ePRO study data Lessons learned from ePRO studies in oncology Implementation science for ePROs How a cancer center is innovating in its approach to proactive symptom monitoring How Carevive technology can facilitate capturing ePROs by monitoring the symptoms patients experience and alerting providers when interventions are necessary for at-risk patients --- Recorded live on January 16, 2019.

Carevive’s Dr. Carrie Stricker led an expert panel the ACCC 44th Annual Meeting and Cancer Center Business Summit in which perspectives were shared on a collaborative research initiative—designed to advance the science of patient engagement—using shared-decision making (SDM) to align clinician and patient understanding of care goals, while systematically enabling electronic capture of Patient-Reported Outcomes (PROs). Features talks from Ethan Basch, Brad Bott, and Nancy Paynter. To view the video please visit our wesbite: https://www.carevive.com/ondemand-patient-engagement-value-based-care/

In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016). Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC. At the conclusion of this podcast episode, listeners should be able to: Utilize new data regarding the evidence-based management of patients with nmCRPC Discuss implications of decisions regarding timing and treatment sequencing for patients with nmCRPC on subsequent therapy Identify ongoing late phase clinical trials in nmCRPC Implement strategies to manage education and symptoms for men with nmCRPC

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML. Presenter Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute Ashley Leak Bryant, PhD, RN-BC, OCN University North Carolina Lineberger Comprehensive Cancer Center